Fig 1.
COVID-19, coronavirus disease-2019; ICU, intensive care unit; NEWS2, National Early Warning Score 2; triple therapy, therapy with lopinavir/ritonavir and hydroxychloroquine.
Table 1.
Characteristics of non-ICU patients treated with a triple therapy (lopinavir/ritonavir and hydroxychloroquine) compared to a control group.
Table 2.
Acute kidney injury and outcome in non-ICU patients.
Table 3.
Multivariable analysis for acute kidney injury adjusted for NEWS2.
Table 4.
Characteristics of ICU patients treated with a triple therapy (lopinavir/ritonavir and hydroxychloroquine) compared to a control group.
Table 5.
Acute kidney injury in ICU patients.
Fig 2.
Lopinavir/ritonavir and hydroxychloroquine (triple therapy) are associated with an increase in the incidence of Acute Kidney Injury (AKI).
Association between triple therapy and AKI (A) in non-intensive care unit (ICU) patients and (B) ICU patients. P-values refer to the total number of AKI; RRT, renal replacement therapy. (C) Association between triple therapy and the maximum serum creatinine value.